Genetic Information

Gene & Transcript Details

Gene
ATM
Transcript
NM_000051.4 MANE Select
Total Exons
Reference Sequence
NC_000011.9
Alternative Transcripts
IDStatusDetails
NM_000051.3 RefSeq Select 13147 nt | 386–9556
NM_000051.4 MANE Select 12915 nt | 151–9321

Variant Details

HGVS Notation
NM_000051.4:c.3403-9C>A
Protein Change
?
Location
Exon 23 (Exon 23 of )
23
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.0 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Uncertain Significance (VUS)
2 publications
Clinical Statement

"This variant has been reported in ClinVar as Uncertain significance (1 clinical laboratories) and as Likely benign (1 clinical laboratories)."

COSMIC Somatic Evidence

Open
COSMIC ID
COSM10175582
Recurrence
1 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene ATM.

Functional Studies & Therapeutic Relevance

Functional Summary

The ATM 3403-9C>A variant has not been functionally characterized.

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Mixed/VUS
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.16 9 bp
- Donor Loss (DL) 0.03 182 bp
+ Acceptor Gain (AG) 0.07 101 bp
+ Donor Gain (DG) 0.0 358 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PVS1

PVS1 (Not Applied)

According to VCEP guidelines, the rule for PVS1 is: "Very Strong Use ATM PVS1 Decision Tree Modification Type: Gene-specific,Strength". The variant c.3403-9C>A is outside the canonical splice sites (+1/+2) and does not introduce a premature stop or frameshift. Therefore, this criterion is not applied.

PS1

PS1 (Not Applied)

According to VCEP guidelines, the rule for PS1 is: "Strong Use for protein changes as long as splicing is ruled-out for both alterations". This variant does not alter an amino acid and no protein change is known. Therefore, this criterion is not applied.

PS2

PS2 (Not Applied)

According to standard ACMG guidelines, the rule for PS2 is: "De novo (both maternity and paternity confirmed) in a patient with the disease and no family history". No de novo or family data are available for this variant. Therefore, this criterion is not applied.

PS3

PS3 (Not Applied)

According to VCEP guidelines, the rule for PS3 is: "Moderate Use when a variant fails to rescue both an ATM specific feature (e.g. phosphorylation of ATM-specific targets) AND radiosensitivity". No functional studies have been performed on this variant. Therefore, this criterion is not applied.

PS4

PS4 (Not Applied)

According to VCEP guidelines, the rule for PS4 is: "Strong Case-control studies; p-value ≤.05 AND (Odds ratio ≥2 OR lower 95% CI ≥1.5)". No case-control or statistical association data are available. Therefore, this criterion is not applied.

PM1

PM1 (Not Applied)

According to standard ACMG guidelines, the rule for PM1 is: "Located in a mutational hot spot and/or critical and well-established functional domain without benign variation". There is no evidence that this intronic region is a mutational hotspot or functional domain. Therefore, this criterion is not applied.

PM2

PM2 (Supporting)

According to VCEP guidelines, the rule for PM2 is: "Supporting Frequency ≤.001% if n=1 in a single subpopulation". The variant is absent from population databases (gnomAD MAF=0%). Therefore, this criterion is applied at Supporting strength.

PM3

PM3 (Not Applied)

According to VCEP guidelines, the rule for PM3 is: "Use ATM PM3/BP2 table for recessive phase data". This variant has no evidence of occurring in trans with a pathogenic variant in a recessive context. Therefore, this criterion is not applied.

PM4

PM4 (Not Applied)

According to standard ACMG guidelines, the rule for PM4 is: "Protein length changes due to in-frame deletions/insertions in a non-repeat region". This intronic variant does not alter protein length. Therefore, this criterion is not applied.

PM5

PM5 (Not Applied)

According to VCEP guidelines, the rule for PM5 is: "Supporting Use for frameshift and truncating variants upstream of p.R3047". This variant is intronic and does not introduce a premature termination codon. Therefore, this criterion is not applied.

PM6

PM6 (Not Applied)

According to standard ACMG guidelines, the rule for PM6 is: "Assumed de novo, but without confirmation of paternity and maternity". No de novo assumption data are available. Therefore, this criterion is not applied.

PP1

PP1 (Not Applied)

According to standard ACMG guidelines, the rule for PP1 is: "Cosegregation with disease in multiple affected family members". No segregation data are available. Therefore, this criterion is not applied.

PP2

PP2 (Not Applied)

According to standard ACMG guidelines, the rule for PP2 is: "Missense variant in a gene with low rate of benign missense variation and where missense is a common mechanism". This is an intronic variant in ATM, a gene where loss-of-function is the primary mechanism. Therefore, this criterion is not applied.

PP3

PP3 (Not Applied)

According to VCEP guidelines, the rule for PP3 is: "Supporting Protein: REVEL >.7333; RNA: At least one well-established in silico predictor shows impact on splicing". SpliceAI predicts low likelihood of splicing impact (max score 0.16) and other in silico tools do not indicate a damaging effect. Therefore, this criterion is not applied.

PP4

PP4 (Not Applied)

According to standard ACMG guidelines, the rule for PP4 is: "Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology". No phenotype data are provided. Therefore, this criterion is not applied.

PP5

PP5 (Not Applied)

According to standard ACMG guidelines, the rule for PP5 is: "Reputable source reports variant as pathogenic". ClinVar entries report uncertain significance and likely benign, not pathogenic. Therefore, this criterion is not applied.

BA1

BA1 (Not Applied)

According to VCEP guidelines, the rule for BA1 is: "Filtering Allele Frequency >.5%". The variant is absent from population databases. Therefore, this criterion is not applied.

BS1

BS1 (Not Applied)

According to VCEP guidelines, the rule for BS1 is: "Filtering Allele Frequency >.05%". The variant is absent from population databases. Therefore, this criterion is not applied.

BS2

BS2 (Not Applied)

According to VCEP guidelines, the rule for BS2 is: "Observed in a healthy adult individual for a dominant disorder". No healthy carrier data are available. Therefore, this criterion is not applied.

BS3

BS3 (Not Applied)

According to VCEP guidelines, the rule for BS3 is: "Moderate Use when a variant rescues both an ATM specific feature AND radiosensitivity". No functional rescue data are available. Therefore, this criterion is not applied.

BS4

BS4 (Not Applied)

According to standard ACMG guidelines, the rule for BS4 is: "Lack of segregation in affected members of a family". No family segregation data are available. Therefore, this criterion is not applied.

BP1

BP1 (Not Applied)

According to standard ACMG guidelines, the rule for BP1 is: "Missense variant in a gene for which only truncating variants cause disease". This is an intronic variant. Therefore, this criterion is not applied.

BP2

BP2 (Not Applied)

According to VCEP guidelines, the rule for BP2 is: "Use ATM PM3/BP2 table for observation in trans with a pathogenic variant". No such data exist. Therefore, this criterion is not applied.

BP3

BP3 (Not Applied)

According to standard ACMG guidelines, the rule for BP3 is: "In-frame deletions/insertions in a repetitive region without a known function". This variant is intronic and not an indel. Therefore, this criterion is not applied.

BP4

BP4 (Supporting)

According to VCEP guidelines, the rule for BP4 is: "Supporting Protein Analysis: REVEL score ≤.249; RNA: at least one well-established in silico predictor shows no impact on splicing". SpliceAI predicts a low likelihood of splicing impact (max score 0.16) and other computational tools do not indicate a deleterious effect. Therefore, this criterion is applied at Supporting strength.

BP5

BP5 (Not Applied)

According to standard ACMG guidelines, the rule for BP5 is: "Variant found in a case with an alternate molecular basis for disease". No such case data exist. Therefore, this criterion is not applied.

BP6

BP6 (Not Applied)

According to standard ACMG guidelines, the rule for BP6 is: "Reputable source reports variant as benign without accessible evidence". ClinVar submissions are conflicting and not solely benign. Therefore, this criterion is not applied.

BP7

BP7 (Not Applied)

According to VCEP guidelines, the rule for BP7 is: "Supporting for synonymous and deep intronic variants beyond ±7 and beyond -40". The variant is at -9, which is within the intronic splicing region but not deep intronic defined as beyond -40. Therefore, this criterion is not applied.